25-Hydroxyvitamin D levels in prevalent Australian dialysis patients

Nephrology

Volumn 14, Issue 6, 2009, Pages 554-559

  Clayton, Philip ^a   Singer, Richard ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Deficiency; Nutrition; Peritoneal dialysis; Renal dialysis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUSTRALIA; BONE METABOLISM; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 69449098316     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01145.x     Document Type: Article

References (58)

1. Holick MF. Vitamin D deficiency. N. Engl. J. Med. 2007 357 : 266 281.
2. Jones G. Expanding role for vitamin d in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin. Dial. 2007 20 : 316 324.
3. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006 311 : 1770 1773.
4. Li YC. Vitamin D regulation of the renin-angiotensin system. J. Cell. Biochem. 2003 88 : 327 331.
5. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 2004 79 : 820 825.
6. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 2007 85 : 1586 1591.
7. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 2008 168 : 1629 1637.
8. Pitts TO, Piraino BH, Mitro R et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J. Clin. Endocrinol. Metab. 1988 67 : 876 881.
9. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol. Dial. Transplant. 1991 6 : 162 169.
10. Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001 86 : 888 894.
11. Somjen D, Weisman Y, Kohen F et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005 111 : 1666 1671.
12. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am. J. Kidney Dis. 2005 45 : 1026 1033.
13. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 71 : 31 8.
14. Mehrotra R, Kermah D, Budoff M et al. Hypovitaminosis D in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2008 3 : 1144 1151.
15. Blair D, Byham-Gray L, Lewis E, McCaffrey S. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J. Ren. Nutr. 2008 18 : 375 382.
16. Jean G, Charra B, Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. J. Ren. Nutr. 2008 18 : 395 399.
17. Taskapan H, Ersoy FF, Passadakis PS et al. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin. Nephrol. 2006 66 : 247 255.
18. Wang AY, Lam CW, Sanderson JE et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am. J. Clin. Nutr. 2008 87 : 1631 1638.
19. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney. Int. 2007 72 : 1004 1013.
20. Elder GJ, Mackun K. 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J. Bone Miner. Res. 2006 21 : 1778 1784.
21. Cuppari L, Carvalho AB, Draibe SA. Vitamin D status of chronic kidney disease patients living in a sunny country. J. Ren. Nutr. 2008 18 : 408 414.
22. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial. Int. 2007 11 : 315 321.
23. Ishimura E, Nishizawa Y, Inaba M et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999 55 : 1019 1027.
24. Branley P, Polkinghorne K, Kerr P. 25-hydroxy vitamin D levels in haemodialysis patients. Abstracts. 44th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, 6-10 September, Newcastle, Australia. Nephrology (Carlton) 2008 13 (Suppl 3 A148.
25. Eknoyan G, Levin A, Levin N. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003 42 : S1 201.
26. Elder GJ. Vitamin D levels, bone turnover and bone mineral density show seasonal variation in patients with chronic kidney disease stage 5. Nephrology (Carlton) 2007 12 : 90 4.
27. Thomas MK, Lloyd-Jones DM, Thadhani RI et al. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 1998 338 : 777 783.
28. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998 351 : 805 806.
29. Chapuy MC, Preziosi P, Maamer M et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 1997 7 : 439 443.
30. Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am. J. Clin. Nutr. 1997 65 : 67 71.
31. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am. J. Med. 2004 116 : 634 639.
32. Ghazali A, Fardellone P, Pruna A et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?. Kidney Int. 1999 55 : 2169 2177.
33. Coen G, Mantella D, Manni M et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005 68 : 1840 1848.
34. Jacob AI, Sallman A, Santiz Z, Hollis BW. Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 1984 114 : 1313 1319.
35. Saha H. Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin. Nephrol. 1994 41 : 290 296.
36. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002 30 : 771 777.
37. Joffe P, Heaf JG. Vitamin D and vitamin-D-binding protein kinetics in patients treated with continuous ambulatory peritoneal dialysis (CAPD). Perit. Dial. Int. 1989 9 : 281 284. (Pubitemid 20026337)
38. Chen WT, Yamaoka K, Nakajima S et al. Evaluation of vitamin D-binding protein and vitamin D metabolite loss in children on continuous ambulatory peritoneal dialysis. Bone Miner 1992 17 : 389 398.
39. Martinez ME, Del Campo MT, Sánchez-Cabezudo MJ, Balaguer G, Rodriguez-Carmona A, Selgas R. Effect of oral calcidiol treatment on its serum levels and peritoneal losses. Perit. Dial. Int. 1995 15 : 65 70.
40. Fournier A, Bordier P, Gueris J et al. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int. 1979 15 : 196 204.
41. Zucchelli P, Catizone L, Casanova S, Fabbri L, Fusaroli M. Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy. Miner. Electrolyte Metab. 1982 7 : 86 96.
42. Halloran BP, Schaefer P, Lifschitz M, Levens M, Goldsmith RS. Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. J. Clin. Endocrinol. Metab. 1984 59 : 1063 1069.
43. Jean G, Terrat JC, Vanel T et al. Evidence for persistent vitamin D 1-Alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron. Clin. Pract. 2008 110 : c58 65.
44. Jean G, Terrat J, Vanel T et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol. Dial. Transplant. 2008 23 : 3670 3676.
45. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006 70 : 654 659.
46. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron. Clin. Pract. 2007 105 : c132 8.
47. Tokmak F, Quack I, Schieren G et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol. Dial. Transplant. 2008 23 : 4016 4020.
48. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009 75 : 88 95.
49. Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am. J. Kidney Dis. 2008 52 : 661 671.
50. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch. Intern. Med. 2008 168 : 397 403. (Pubitemid 351350586)
51. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J. Am. Soc. Nephrol. 2008 19 : 1613 1619.
52. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006 70 : 771 780.
53. Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008 74 : 1070 1078.
54. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. 2004 19 : 179 184.
55. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005 16 : 1115 1125.
56. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GFM. Meta-analysis vitamin D compounds in chronic kidney disease. Ann. Intern. Med. 2007 147 : 840 853.
57. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol. Dial. Transplant. 2009 24 : 963 972.
58. Singer R, Rhodes HC, Chin G, Kulkarni H, Ferrari P. High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. Nephrology (Carlton) 2008 13 : 17 22.